Kolon Life Science Inc. (KOSDAQ:102940)
South Korea · Delayed Price · Currency is KRW 12,140
-360 (-2.88%)
Nov 12, 2026, 3:30 PM KST
Kolon Life Science Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 211,439 | 208,982 | 161,387 | 124,639 | 161,584 | 165,485 |
Revenue Growth | 17.09% | 29.49% | 29.48% | -22.86% | -2.36% | 27.87% |
Gross Profit Gross Profit Growth | 58,376 | 55,778 | 16,744 | 12,296 | 37,017 | 37,104 |
Operating Income Operating Income Growth | 18,373 | 17,572 | -22,084 | -24,095 | 2,642 | 4,249 |
Net Income Net Income Growth | 34,628 | 24,960 | -93,086 | -30,726 | 2,133 | -1,375 |
Earnings Per Share EPS Growth | 2402.87 | 1823.84 | -7794.19 | -2692.37 | 169.00 | -121.00 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Bio Business Division Bio Business Division Growth | 5,913 | 3,850 | 2,606 | 254.86 | 16,112 | 1,086 |
Chemical Business Division Chemical Business Division Growth | 205,526 | 205,131 | 158,781 | 124,384 | 145,472 | 164,400 |
Total Total Growth | 211,439 | 208,982 | 161,387 | 124,639 | 161,584 | 165,485 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 31,696 | 10,636 | 12,498 | 7,561 | 6,371 | 27,910 |
Total Debt Total Debt Growth | 157,334 | 103,730 | 126,598 | 107,863 | 73,916 | 68,925 |
Net Cash (Debt) Net Cash Growth | -125,638 | -93,094 | -114,100 | -100,301 | -67,545 | -41,015 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -8432.05 | -6496.63 | -9553.71 | -8788.83 | -5344.94 | -3597.74 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -31,222 | 10,209 | -14,085 | -24,866 | -20,854 | -16,187 |
Capital Expenditures CapEx Growth | -27,787 | -38,264 | -8,194 | -10,144 | -6,305 | -4,413 |
Free Cash Flow Free Cash Flow Growth | -59,009 | -28,055 | -22,279 | -35,009 | -27,159 | -20,600 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 27.61% | 26.69% | 10.38% | 9.87% | 22.91% | 22.42% |
Operating Margin | 8.69% | 8.41% | -13.68% | -19.33% | 1.64% | 2.57% |
Pretax Margin | 16.63% | 12.32% | -57.68% | -26.96% | 2.55% | -2.42% |
Profit Margin | 16.38% | 11.94% | -57.68% | -24.65% | 1.32% | -0.83% |
FCF Margin | -27.91% | -13.43% | -13.80% | -28.09% | -16.81% | -12.45% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.05 | 26.73 | - | - | 146.58 | - |
Forward PE | - | 30.73 | 30.73 | 30.73 | 30.73 | 30.73 |
PS Ratio | 0.75 | 3.19 | 1.77 | 2.35 | 1.94 | 2.98 |